Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 24, Issue 2, Pages 89-95Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/09546634.2011.595383
Keywords
atopic dermatitis; bullous pemphigoid; dermatomyositis; leflunomide in dermatology; primary Sjogren's syndrome; psoriasis; psoriatic arthritis; sarcoidosis; systemic lupus erythematosus; systemic sclerosis; Wegener's granulomatosis
Categories
Ask authors/readers for more resources
Leflunomide, an isoxazole derivative, is a disease-modifying antirheumatic drug. It has successfully been used for the treatment of rheumatoid arthritis as a feasible alternative to methotrexate. Recently, leflunomide has been used in certain dermatologic conditions. Medline/PubMed search revealed only 201 articles of its application in dermatologic conditions, of which 21 were relevant for inclusion. Prime mode of action of leflunomide is through the inhibition of dihydroorotate dehydrogenase, a key enzyme in the de novo pyrimidine synthesis pathway used by lymphocytes for clonal expansion. The current level of evidence and strength of recommendation suggest its use in psoriasis and psoriatic arthritis. However, the use of leflunomide in severe atopic dermatitis, systemic lupus erythematosus, Wegener's granulomatosis, primary Sjogren's syndrome, bullous pemphigoid, dermatomyositis, sarcoidosis and systemic sclerosis still requires further evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available